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Aims:The SF-Qualiveen is a short questionnaire thatmeasures the impact of urinary
symptoms on the quality of life of patients with urological dysfunction due to
neurological disorders. The aim of this study is to translate, culturally adapt and
validate a Dutch version of the SF-Qualiveen for use in Multiple Sclerosis (MS)
patients.
Methods:Cross-cultural adaptation of the original English SF-Qualiveen intoDutch
was performed according to standardized guidelines. Adult MS patients with
symptomatic urinary disorderswho visited theUrology or Rehabilitation outpatient
clinic of the Erasmus Medical Center completed the SF-Qualiveen and the Urinary
Distress Inventory-6 (UDI-6), that evaluates bother caused by lower urinary tract
symptoms and was used as a gold standard, at baseline and 1-2 weeks later. A
control group recruited from the Otolaryngology outpatient clinic completed the
questionnaires once. Reliability and validity were determined.
Results: Fifty MS patients and 50 controls were included. SF-Qualiveen scores in
patients were higher than in controls (on a scale of 0-4: 1.73 vs. 0.34; P< 0.001).
Internal consistency (Cronbach's alpha >0.8) and reproducibility (Intraclass
correlation coefﬁcients >0.8) were good for the total SF-Qualiveen. Content
validity was adequate and a signiﬁcant relationship between SF-Qualiveen and
UDI-6 (r= 0.510-0.479, P< 0.001) conﬁrmed good criterion validity.
Conclusions: The Dutch SF-Qualiveen showed good measurement properties. We
recommend its use to measure urinary-speciﬁc quality of life in MS patients in
research and clinical practice in the Netherlands.
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1 | INTRODUCTION
Urological dysfunction is common in patients with multiple
sclerosis (MS), with prevalence reported as high as 32-97%.1
This variance is at least partly related to the stage of the
progression of the disease. While urinary storage symptoms
(urgency, frequency, and urinary incontinence) due to
overactive contractions of the detrusor muscle often dominate
in earlier disease, voiding problems (straining, intermittence,
residual urine, and retention) due to detrusor-sphincter
dyssynergia often arise in addition to the storage symptoms
in progressed disease.1 This bladder dysfunction is associated
with an important worsening of the quality of life in patients
with MS.2
As differences have been noted between doctors’ and
patients’ perceptions of the impact of a chronic disease like
MS, there is a need for direct measurements of patients’
experiences to be informed about their perception of the
impact of the disease on the quality of life.3 The European
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Association of Urology (EAU) guidelines on Neuro-
Urology highlight quality of life as an import aspect in
the management of neuro-urological patients. The
Qualiveen4 and its more practical short form
(SF-Qualiveen)5 are validated questionnaires for patients
with MS evaluating the urinary-speciﬁc quality of life by
assessing the impact of a broad range of bladder problems.
The Qualiveen or SF-Qualiveen is recommended by the
EAU for the assessment of health related quality of life in
this patient group.6
The Qualiveen contains 30 questions. It was developed
and validated in French for both spinal cord injury and MS
patients4,7 and underwent successful cross-cultural adapta-
tion into English,8 German,9 Italian,10 Portuguese,11 and
Spanish.12 The SF-Qualiveen with eight questions proved to
have good measurement properties in MS patients and is
currently available in French and English.5 The aim of our
study is to translate, culturally adapt, and validate a Dutch
version of the SF-Qualiveen in MS patients, so as to make the
SF-Qualiveen suitable for MS patients in the Netherlands in
both research and clinical practice.
2 | MATERIALS AND METHODS
2.1 | Study design and population
This is a single-center, prospective (cohort) validation
study. The local medical research ethics committee
reviewed the research proposal with the number
MEC-2014-534 and concluded that the rules as stated in
the Medical Research Involving Human Subjects Act do not
apply.
Adult MS patients with urinary symptomatology, who
visited the Urology outpatient clinic of the Erasmus
University Medical Center (Erasmus MC) Rotterdam, the
Netherlands, between October 2015 and April 2016 were
invited for the study. MS patients with similar symptoms
who visited the Rehabilitation outpatient clinic of the
Erasmus MC between February 2016 and April 2016 were
invited as well. Patients with Dutch language difﬁculties,
cognitive impairment, active malignant tumors, acute
attacks of MS (deﬁned as an acute episode of focal
neurological disturbance), symptomatic urinary tract
infections, and patients who changed treatment within the
test-retest period were excluded. Patients were asked to
complete two questionnaires (SF-Qualiveen and UDI-6);
during a hospital visit (baseline) and 1-2 weeks later at
home. All patients provided written informed consent.
Patient and disease characteristics were retrieved from the
medical ﬁles.
Adult patients who visited the Otolaryngology outpatient
clinic between March and May 2016 were invited for the
study as well. We considered these patients a proper control
group, since Otolaryngology pathology is often limited to the
organ and has no relationship with bladder problems. This
group completed the questionnaires only once. Exclusion
criteria for this group were: neuro-urological dysfunction
(patients reporting both bladder symptoms and MS or spinal
cord injury), cognitive impairment and Dutch language
difﬁculties.
2.2 | Questionnaires
The SF-Qualiveen5 is a validated short version of the
Qualiveen-304 questionnaire and evaluates urinary-speciﬁc
quality of life. The SF-Qualiveen consists of eight questions
and reports on four domains of two questions each: bother
with limitations, fears, feelings, and frequency of limitations.
Table 1 displays the items of the SF-Qualiveen. Responses
are given on a 5-point Likert like scale, where a score of 0
indicates “no impact” and 4 “high impact.”The SF-Qualiveen
total score is calculated as the mean of the eight responses and
the domain scores are calculated as the mean score of the
responses per domain.
The Dutch Urinary Distress Inventory (UDI-6) eval-
uates bother caused by lower urinary tract symptoms.13 It
consists of six questions and reports on three domains:
irritative, stress, and obstructive/discomfort symptoms.
Answers can be given on a 4-point Likert like scale. The
questionnaire is validated, but not speciﬁcally for neuro-
urological patients.
TABLE 1 Items of the SF-Qualiveen
Domains: Questions:
Bother with limitations 1. In general, do your bladder problems complicate your life?
2. Are you bothered by the time spent passing urine or realizing catheterization?
Fears 3. Do you worry about your bladder problems worsening?
4. Do you worry about smelling of urine?
Feeling 5. Do you feel worried because of your bladder problems?
6. Do you feel embarrassed because of your bladder problems?
Frequency of limitations 7. Is your life regulated by your bladder problems?
8. Can you go out without planning anything in advance?
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2.3 | Cross-cultural adaptation
The cross-cultural adaptation of the original English
SF-Qualiveen into the Dutch language was performed
according to standardized guidelines for linguistic valida-
tion.14 The forward-translation was performed by two
professional native Dutch-speaking translators separately,
followed by a consensus meeting of these two and the
primary investigator (SR). The consensus version was
backward translated by a native English speaking translator.
During a consensus meeting with the Dutch translators, the
English translator and the primary investigator (SR) a few
minor adjustments were made. Two urologists (BB and JS)
proof-read and agreed on this version of the Dutch
SF-Qualiveen. It was then evaluated on content validity,15
i.e., pre-tested, in face-to-face interviews with patients
during August and September 2015. We aimed to include at
least 10 MS patients for the face-to-face interviews. These
patients were ﬁrst asked to complete the questionnaire.
Thereafter, content and wording of the questions were
discussed with the patients and suggestions for improve-
ment were solicited.
2.4 | Validation − reliability
2.4.1 | Internal consistency
This is the intercorrelation of the questions of a questionnaire
and demonstrates if the questions measure the same
underlying concept. The correlation between the questions
of the SF-Qualiveen for the total score and for the separate
domains were measured by determination of the Cronbach's
alpha. If Cronbach's alpha was between 0.7 and 0.95, internal
consistency was considered good.15
2.4.2 | Reproducibility
The intraclass correlation coefﬁcients (ICC) for agreement
were calculated for the overall SF-Qualiveen score and for the
four domains to test the test-retest reliability. A score of 0.7 or
higher was considered good.15
2.4.3 | Limits of agreement
The limits of agreement (LOA) were calculated as the mean
change in scores of repeatedmeasurements ±1.96 × SD of the
changes. Provided differences within the LOA could be
interpreted as measurement error and would not be clinically
important.16
2.5 | Validation − validity
2.5.1 | Content validity
During the cross-cultural adaptation process, content validity
was assessed by patient interviews.
2.5.2 | Construct validity
Predeﬁned hypotheses about the relation of the SF-Qualiveen
to other measures were tested:
 “Patients with higher SF-Qualiveen scores (indicating
higher impact on urinary-related quality of life) will have
higher scores on the UDI-6 (indicating more bother of
urinary symptoms).” The association between the
SF-Qualiveen and UDI-6 scores will be assessed using
the Pearson's correlation coefﬁcient in case of a linear
association.
 “The SF-Qualiveen scores in the patient group will be
higher than the reference group.” The Student's t-test will
be used to assess the differences between groups.
2.5.3 | Criterion validity
For the SF-Qualiveen no perfect gold standard exists. In the
absence of a perfect gold standard the UDI-6 is used as a
gold standard to determine criterion validity. The correla-
tion of the SF-Qualiveen to the UDI-6 is determined by
using the Pearson correlation coefﬁcient in case of a linear
association.
2.5.4 | Floor and ceiling effects
If more than 15% of respondents achieved the highest or
lowest possible score, ﬂoor or ceiling effects are presumed to
be present. We calculated the percentages of patients with the
highest or lowest possible score.
2.6 | Further statistical methods
We aimed at a sample size of 50 MS patients and 50 control
persons based on guidelines for validation of question-
naires.15 SPSS version 21 was used to perform the statistical
analyses in this study. Mean ± standard deviations were used
to present descriptive results for continuous data and counts
and percentages for discrete data. Differences between
groups were tested with χ2 tests for categorical variables
and with Student's t-tests for continuous variables. P-values
of less than 0.05 were considered to reﬂect statistical
signiﬁcance.
3 | RESULTS
Fifty-six MS patients with symptomatic urinary disorders
were initially included in the study. Patients signed informed
consent and ﬁlled in the baseline questionnaire. Six patients
were excluded afterwards for the following reasons: four
patients did not return the second questionnaire for unknown
reasons, one refused to ﬁll in the second questionnaire and
one changed treatment within the test-retest period.
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Eventually the data of 50 MS patients could be used for
analyses. The mean time between completing the ﬁrst and
second questionnaire was 15.7 ± 10.6 days.
Fifty persons who visited the Otolaryngology outpatient
clinic of the Erasmus MC between March and May 2016
completed the questionnaires once as a control group. Table 2
displays the characteristics of the included MS patients and
controls. The MS patient group was signiﬁcantly older
(P=0.013) and had more females (P=0.002) than the control
group. Most patients had relapsing-remitting MS (60%),
were limited in walking (46%), voided without catheteriza-
tion (72%), and experienced both storage and voiding
urinary symptoms (70%).
3.1 | Validation − reliability
3.1.1 | Internal consistency
With Cronbach's alpha's of >0.8, the internal consistency for
the total SF-Qualiveen can be considered good. (Table 3)
With a Cronbach's alpha of >0.7 the domains “bother with
limitations” and “feeling” showed a good internal consis-
tency as well. The domain “frequency of limitations” showed
moderate internal consistency and the domain “fears” showed
weak internal consistency.
3.1.2 | Reproducibility
The ICCs for agreement for the total SF-Qualiveen and the
four domains were all higher than 0.7, indicating good
reproducibility. (Table 4)
3.1.3 | Limits of agreement
The LOA ranges of the total SF-Qualiveen and the domains
are presented in Table 4. A change of less than 0.76 in the total
SF-Qualiveen score could be interpreted as measurement
error.
3.2 | Validation − validity
3.2.1 | Content validity
This was evaluated in face-to-face interviews with 11 MS
patients and 12 other neuro-urological patients. The
importance of all questions, to assess the broad range of
bladder problems patients experience, was conﬁrmed by the
majority of patients. The Dutch-version questionnaire was
found generally accessible, clear, easy to understand, and
fast to complete and it was not necessary to make
adjustments.




Age at examination (years) 50.3 ± 11.7 42.3 ± 14.2 0.013
Gender
Male 11 (22.0%) 26 (52.0%) 0.002
Female 39 (78.0%) 24 (48.0%)
MS characteristics
Duration of MS since diagnosis (years) 13.3 ± 9.0
MS course
Relapsing-remitting 30 (60.0%)
Primary progressive 5 (10.0%)
Secondary progressive 11 (22.0%)
Missing 4 (8.0%)
Mobility
Fully ambulatory 16 (32.0%)
Limited walking 23 (46.0%)
Wheelchair bound 10 (20.0%)
Missing 1 (2.0%)
Urinary symptoms




Storage + voiding 35 (70.0%)
Manner of bladder emptying
(normal) voiding 36 (72.0%)
Intermittent catheterization 10 (20.0%)
Indwelling catheter 4 (8.0%)
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3.2.2 | Construct validity
Both predeﬁned hypotheses about the relation of the
SF-Qualiveen score to other measures were conﬁrmed:
 We found a signiﬁcant linear correlation between the total
score of SF-Qualiveen and total score of UDI-6 in the
patient group (T0: r= 0.510 and P< 0.001; T1: r= 0.479
and P< 0.001). This conﬁrmed the hypothesis “patients
with higher SF-Qualiveen scores have higher UDI-6
scores.”
 The mean of the total score of the SF-Qualiveen differed
between patient and the control group (1.73 vs. 0.34;
P< 0.001). The hypothesis “SF-Qualiveen scores in the
patient group are higher than in the control group” is
hereby conﬁrmed.
3.2.3 | Criterion validity
A signiﬁcant relationship was found between the UDI-6
total score, and the SF-Qualiveen total score in both MS
patient group (T0: r = 0.510 and P< 0.001; T1: r = 0.479
and P< 0.001) and the control group (r= 0.632 and
P< 0.001).
3.2.4 | Floor and ceiling effects
In the patient group no ﬂoor or ceiling effects were found in
total or domain scores. Two percent of patients had the lowest
possible total score and no patients had the highest possible
score. Four to ten percent of the patients reported the lowest
possible scores for the separate domains. Zero to four percent
of the patients reported the highest possible scores for the
separate domains.
In the control group,ﬂoor effectswere found in all domains
and in the total score. (domains: 58-86% and total score: 50%).
No ceiling effects were found in the control group.
4 | DISCUSSION
We translated the SF-Qualiveen into Dutch, and culturally
adapted and validated it for use in MS patients. The
measurement properties demonstrated the Dutch version of
the SF-Qualiveen to be valid, reliable, and consistent. This
enables the use of the SF-Qualiveen for future research and
clinical practice in the Netherlands.
For chronic diseases like MS, quality of life is an
important aspect of healthcare. The urinary symptoms that
are often described in patients with MS can diminish the
quality of life.2 This study makes it possible for Dutch-
speaking MS patients to directly measure the impact of
urinary symptoms on the quality of life with the
SF-Qualiveen. We chose to translate and validate the short
form because this is more practical, easier to implement into
research, and clinical practice, and causes less patient
burden to complete. In validation studies of the Qualiveen
the length of the questionnaire has been mentioned as a
limitation.11,12 The Dutch SF-Qualiveen can be a valuable
addition to diagnostics, so as the EAU guidelines
recommends its use.6
The Cronbach's alpha of >0.8 indicates good internal
consistency for the entire SF-Qualiveen questionnaire. For
the development of the SF-Qualiveen Bonniaud et al.5
selected two questions per domain of the Qualiveen-30,
based on the most responsive items to represent that
domain. The authors did not address the internal consis-
tency of the SF-Qualiveen, neither for the total score, nor
for the domain scores. The internal consistency of a
questionnaire is dependent upon the number of items in a
scale.15 In a short questionnaire like the 8-item SF-
Qualiveen categorization into four domains might therefore
be questioned. In our study, the domains “bother with
limitations” and “feeling” showed good internal consis-
tency and the domain “frequency of limitations” showed
moderate internal consistency. The domain “fears” showed
weak internal consistency. Although its two questions (see
TABLE 3 Internal consistency − Cronbach's alpha (n= 50 MS patients)
Test Re-test
SF-Qualiveen total 0.84 0.85
SF-Qualiveen subscales:
Bother with limitations 0.72 0.78
Fears 0.26 0.40
Feeling 0.77 0.75
Frequency of limitations 0.43 0.66
TABLE 4 Reproducibility of SF-Qualiveen
Test (mean ± SD) Re-test (mean ± SD) Mean change (mean ± SD) ICC LOA
SF-Qualiveen total score 1.73 ± 0.84 1.73 ± 0.84 0.00 ± 0.39 0.90 −0.76 to 0.76
Bother with limitations 1.67 ± 1.10 1.70 ± 1.06 0.03 ± 0.61 0.84 −1.17 to 1.23
Fears 1.59 ± 0.98 1.58 ± 0.96 −0.01 ± 0.53 0.85 −1.05 to 1.03
Feeling 1.56 ± 1.09 1.50 ± 1.09 −0.06 ± 0.73 0.78 −1.50 to 1.38
Frequency of limitations 2.09 ± 0.95 2.13 ± 1.02 0.00 ± 0.39 0.72 −0.76 to 0.76
SD, standard deviation; ICC, intraclass correlation coefﬁcient; LOA, limits of agreement.
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Table 1) are both important (as was conﬁrmed during cross-
cultural adaptation), the answers to these questions do not
necessarily have to be associated. It is doubtful if the two
questions measure the same underlying construct of “fears.”
A potential explanation for the moderate internal consis-
tency of the questions within the domain “frequency of
limitations” (Table 1) is that patients’ answers to the last
question might not be exclusively related to their bladder
problems. The question arising from our study results on the
internal consistency of the separate domains and that each
consists of only a small number of questions, is whether the
domains of the SF-Qualiveen can still be considered as
actual domains. Therefore, we investigated this issue by
performing a factor analysis of the eight questions of the
SF-Qualiveen. This resulted in the identiﬁcation of two
components within the questionnaire. The ﬁrst component
is represented by the ﬁrst seven questions and the second
component by question 8. This indicates that the four
Qualiveen domains can no longer be identiﬁed in the
SF-Qualiveen and that question 8 might assess a different
construct than the other questions. This reasoning is
conﬁrmed by the Cronbach's alpha rising from 0.835 to
0.855 at baseline and from 0.851 to 0.871 at re-test when
excluding question 8 from the analysis. Therefore, exclu-
sion of question 8 from the questionnaire can be considered.
In view of the good internal consistency of the total
SF-Qualiveen, the lack of identiﬁcation of four domains in
the SF-Qualiveen, the patients agreement on the importance
of all 8 questions of the questionnaire (content validity), and
to support consistent (international) usage of the
SF-Qualiveen we recommend to use the entire
SF-Qualiveen questionnaire and not the separate domains.
The ICCs showed a good reproducibility of the Dutch
SF-Qualiveen. These ICCs are lower than reported in the
original Qualiveen-30 questionnaire,4 but are comparable to
those found in the French and English validation study of
the SF-Qualiveen.5 The lower ICCs for the SF-Qualiveen
are probably to the result of the shortening. We believe that
the advantages of the short SF-Qualiveen (more practical,
less patient burden, and easier to implement into practice)
outweigh this minor disadvantage.
The Dutch SF-Qualiveen showed good validity. Predeﬁned
hypotheses to test construct validity could be conﬁrmed. Patients’
scores on the SF-Qualiveen were signiﬁcantly higher than those
of controls,which demonstrates gooddiscriminative ability of the
SF-Qualiveen. Furthermore, a correlationwas found between the
UDI-6 as a gold standard and the SF-Qualiveen. This conﬁrmed
good criterion validity. In the patient group no ﬂoor or ceiling
effects were found. As expected, a ﬂoor-effect was found in the
control group (no urological patients).
One of the strengths of our study is that we followed all
proposedquality criteria for the validation of a questionnaire of
Terwee et al.15 Furthermore, we included a very homogeneous
study population of only MS patients. Therefore, we conclude
that the SF-Qualiveen can be used to measure the urinary-
speciﬁc quality of life for MS patients with symptomatic
functional urologic disorders. Further research is needed to
validate the questionnaire for other neurological diseases such
as spinal cord injury.
A limitation of this study is that we were not yet able to
measure the responsiveness of the SF-Qualiveen. Another
limitation is that the exact response rate cannot be established.
We aimed at including all consecutive eligible patients. Study
inclusions were performed by selected urologists and a
rehabilitation specialist specialized in the treatment of MS
patients. We were not able to establish whether indeed all
eligible patients were approached by these physicians and
how many patients declined to participate. We could also
have missed a small number of eligible patients who visited
other (non-speciﬁcally MS specialized) urologists or rehabil-
itation specialists at our hospital during the inclusion period.
Furthermore, there was no perfect gold standard question-
naire available. A perfect gold standard would be a
questionnaire that is available in Dutch, commonly used,
measures the urinary-speciﬁc quality of life and is validated
in neuro-urological patients. In the absence of a perfect gold
standard we chose the UDI-6, a commonly used question-
naire, which evaluates bother by lower urinary tract
symptoms to function as the gold standard. Finally, due to
the single-center design of the study in a referral center, the
generalizability of the questionnaire is questionable. On the
other hand, the SF-Qualiveen showed good measurement
properties in the original validation multicenter study.5
5 | CONCLUSIONS
In conclusion, the Dutch version of the SF-Qualiveen
showed good measurement properties. We recommend
using the entire Dutch version of the short and practical
SF-Qualiveen to measure urinary-speciﬁc quality of life
experienced by MS patients in both research and clinical
practice in the Netherlands. SF-Qualiveen outcomes can
support healthcare professionals in treatment decision
making to optimize patients’ quality of life.
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